Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1129Triple Negative Breast Neoplasms 85Neoplasm Metastasis 62Neoplasms 40Breast Neoplasms, Male 20Prostatic Neoplasms 19Carcinoma, Intraductal, Noninfiltrating 19Neutropenia 18HER2-positive Breast Cancer 17Breast Carcinoma In Situ 17Pain 16Carcinoma, Ductal, Breast 16Hot Flashes 15Lung Neoplasms 14Inflammatory Breast Neoplasms 14Breast Diseases 14Brain Neoplasms 14Osteoporosis 13Multiple Myeloma 13Advanced Breast Cancer 13Recurrence 12Ovarian Neoplasms 12Lymphoma, Non-Hodgkin 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Testicular Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Follicular 10

Interventions

liposomal doxorubicin 1Vinorelbine 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Genetic Predisposition to Disease × Breast × Clear all
NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
300 enrolled
Breast

Breast Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡